| Literature DB >> 24058336 |
Amy C Reichelt1, Jonathan L C Lee.
Abstract
Memory reconsolidation has been observed across species and in a number of behavioral paradigms. The majority of memory reconsolidation studies have been carried out in Pavlovian fear conditioning and other aversive memory settings, with potential implications for the treatment of post-traumatic stress disorder. However, there is a growing literature on memory reconsolidation in appetitive reward-related memory paradigms, including translational models of drug addiction. While there appears to be substantial similarity in the basic phenomenon and underlying mechanisms of memory reconsolidation across unconditioned stimulus valence, there are also notable discrepancies. These arise both when comparing aversive to appetitive paradigms and also across different paradigms within the same valence of memory. We review the demonstration of memory reconsolidation across different aversive and appetitive memory paradigms, the commonalities and differences in underlying mechanisms and the conditions under which each memory undergoes reconsolidation. We focus particularly on whether principles derived from the aversive literature are applicable to appetitive settings, and also whether the expanding literature in appetitive paradigms is informative for fear memory reconsolidation.Entities:
Keywords: NMDA antagonists; appetitive conditioning; drug addiction; fear memory; memory reconsolidation; post-traumatic stress disorder; protein synthesis inhibitors
Year: 2013 PMID: 24058336 PMCID: PMC3766793 DOI: 10.3389/fnbeh.2013.00118
Source DB: PubMed Journal: Front Behav Neurosci ISSN: 1662-5153 Impact factor: 3.558
Summary of aversive and appetitive paradigms including details of target structures and mechanisms.
| Aversive | Protein synthesis inhibition—Anisomycin | Lateral amygdala | Nader et al., | |
| Cued fear conditioning | ||||
| NMDA antagonism—MK-801 | Systemic | Ben Mamou et al., | ||
| BLA | Ben Mamou et al., | |||
| B-adrenergic antagonism—propranolol | Lateral amygdala | Debiec and Ledoux, | ||
| Systemic | Kindt et al., | |||
| Protein kinase A inhibitor | Lateral amygdala | Tronson et al., | ||
| Cannabinoid CB1 agonist—WIN55212-2 | BLA | Lin et al., | ||
| Contextual fear conditioning | Protein synthesis inhibition—Anisomycin | Hippocampus | Debiec et al., | |
| Transcription factor inhibition—Zif268 | Hippocampus | Lee et al., | ||
| Amygdala | Lee et al., | |||
| NMDA antagonism—AP5 | Hippocampus | Lee and Hynds, | ||
| NMDA antagonism—MK-801 | Systemic | Charlier and Tirelli, | ||
| β-adrenergic antagonism—Propranolol | Systemic | Abrari et al., | ||
| GABAA agonist - midazolam | Systemic | Bustos et al., | ||
| Inhibitory avoidance | Protein synthesis inhibition—Anisomycin | Amygdala | Milekic et al., | |
| β-adrenergic antagonism—Propranolol | Systemic | Przybyslawski et al., | ||
| Acetylcholine antagonist—α 7 nicotinic antagonist | Hippocampus | Boccia et al., | ||
| Transcription inhibitor—NF-κB | Hippocampus | Boccia et al., | ||
| mTOR inhibition | Hippocampus and BLA | Jobim et al., | ||
| BLA | Pedroso et al., | |||
| Conditioned taste aversion | Protein synthesis inhibition—Cyclohexamide | Systemic | Flint and Marino, | |
| Anisomycin | Insular cortex | Eisenberg et al., | ||
| Protein kinase inhibition | BLA | Koh and Bernstein, | ||
| Cannabinoid CB1 agonist—WIN55212-2 | Insular cortex | Kobilo et al., | ||
| NMDA agonism—d-cycloserine | Systemic | Lee et al., | ||
| Cued fear conditioning | Cannabinoid CB1 agonist—WIN55212-2 | Hippocampus | de Oliveira Alvares et al., | |
| Contextual fear conditioning | NMDA agonism—d-cycloserine | Systemic | Yamada et al., | |
| Appetitive | Protein synthesis inhibition—Anisomycin | BLA | Lee et al., | |
| Conditioned reinforcement | ||||
| Transcription factor inhibition—Zif268 | BLA | Lee et al., | ||
| NMDA antagonist—AP5 | BLA | Milton et al., | ||
| MK-801 | Systemic | Lee and Everitt, | ||
| β-adrenergic antagonism—Propranolol | Systemic | Milton et al., | ||
| Sign-tracking and Pavlovian—Instrumental transfer | NMDA antagonist—MK-801 | Systemic | Lee and Everitt, | |
| B-adrenergic antagonism—Propranolol (cocaine sign tracking only) | Systemic | Milton and Everitt, | ||
| Goal tracking | NMDA antagonist—MK-801 | Systemic | Reichelt and Lee, | |
| Conditioned place preference | Protein synthesis inhibition—Anisomycin | BLA | Milekic et al., | |
| NMDA antagonist—AP5 | Hippocampus | Sakurai et al., | ||
| MK-801 | Systemic | Sadler et al., | ||
| β-adrenergic antagonism—Propranolol | Systemic | Bernardi et al., | ||
| GABAA agonist—Midazolam | Systemic | Robinson and Franklin, | ||
| Muscarinic acetylcholine agonist—Scopolamine | Systemic | Kelley et al., | ||
| Transcription inhibitor—NF-κB | Intraventricular | Yang et al., | ||
| -cdK5 | BLA | Li et al., | ||
| -ERK | Frontal cortex | Li et al., | ||
| Odor-reward discrimination | NMDA antagonist—AP5 | Intraventricular | Torras-Garcia et al., | |
| NMDA agonist—d-cycloserine | BLA | Lee et al., | ||
| Conditioned reinforcement | ||||
| Odor-reward discrimination | NMDA agonist—d-cycloserine | BLA | Portero-Tresserra et al., | |
| Conditioned place preference | NMDA agonist—d-cycloserine | Systemic | Kelley et al., |